Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Agrippal (2005-2006 Formulation) in Adults and Elderly
NCT00316615Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2005
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of subunit inactivated influenza vaccine in influenza, sponsored by Novartis. Primary endpoints: Seroprotection Rate (CHMP criteria) at 21 days, Seroconversion Rate (CHMP criteria) at 21 days and 1 more. Started Jun 2005; status: completed.
02
Drugs
subunit inactivated influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00316615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00316615.